BR112023003432A2 - Regime de tratamento para o tratamento de doenças autoimunes - Google Patents

Regime de tratamento para o tratamento de doenças autoimunes

Info

Publication number
BR112023003432A2
BR112023003432A2 BR112023003432A BR112023003432A BR112023003432A2 BR 112023003432 A2 BR112023003432 A2 BR 112023003432A2 BR 112023003432 A BR112023003432 A BR 112023003432A BR 112023003432 A BR112023003432 A BR 112023003432A BR 112023003432 A2 BR112023003432 A2 BR 112023003432A2
Authority
BR
Brazil
Prior art keywords
treatment
autoimmune diseases
regime
new
treatment regimen
Prior art date
Application number
BR112023003432A
Other languages
English (en)
Inventor
Boschert Ursula
Wiederman Urs
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112023003432A2 publication Critical patent/BR112023003432A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REGIME DE TRATAMENTO PARA O TRATAMENTO DE DOENÇAS AUTOIMUNES. A presente invenção refere-se a um novo regime de tratamento para o tratamento de distúrbios autoimunes. O dito novo regime de tratamento fornece de preferência um tratamento eficaz de distúrbios autoimunes com um perfil de segurança vantajoso e/ou uma alta qualidade de vida para o paciente. De preferência, o dito novo regime de tratamento proporciona uma relação benefício-risco vantajosa para pacientes ameaçados pelo risco de infecções.
BR112023003432A 2020-09-10 2021-09-10 Regime de tratamento para o tratamento de doenças autoimunes BR112023003432A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062706795P 2020-09-10 2020-09-10
US202062706819P 2020-09-11 2020-09-11
US202063198971P 2020-11-25 2020-11-25
US202063199265P 2020-12-16 2020-12-16
US202163149196P 2021-02-12 2021-02-12
US202163175318P 2021-04-15 2021-04-15
PCT/EP2021/074928 WO2022053608A1 (en) 2020-09-10 2021-09-10 Novel treatment regimen for the treatment of autoimmune disorders

Publications (1)

Publication Number Publication Date
BR112023003432A2 true BR112023003432A2 (pt) 2023-03-21

Family

ID=78080246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003432A BR112023003432A2 (pt) 2020-09-10 2021-09-10 Regime de tratamento para o tratamento de doenças autoimunes

Country Status (10)

Country Link
US (2) US20240226284A1 (pt)
EP (1) EP4210710A1 (pt)
JP (1) JP2023541877A (pt)
KR (1) KR20230066402A (pt)
AU (1) AU2021342333A1 (pt)
BR (1) BR112023003432A2 (pt)
CA (1) CA3194812A1 (pt)
IL (1) IL301246A (pt)
MX (1) MX2023002843A (pt)
WO (1) WO2022053608A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023242285A1 (en) 2022-06-15 2023-12-21 Vektor Pharma Tf Gmbh Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PT801571E (pt) 1994-12-22 2002-12-31 Ortho Pharma Corp Formulacoes soluveis de 2-cloro-2'-desoxiadenosina
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
US7572909B2 (en) 2002-09-25 2009-08-11 Brigham Young University Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine
EP1608343B1 (en) 2003-03-28 2016-04-27 Ares Trading S.A. Cladribine formulations for improved oral and transmucosal delivery
DK2272503T3 (da) 2003-03-28 2013-05-21 Ares Trading Sa Orale formuleringer af cladribin
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
BR112020010282A2 (pt) * 2017-11-24 2020-11-17 Merck Patent Gmbh regime de cladribina para uso no tratamento de formas progressivas de esclerose múltipla

Also Published As

Publication number Publication date
EP4210710A1 (en) 2023-07-19
IL301246A (en) 2023-05-01
JP2023541877A (ja) 2023-10-04
US20240335529A1 (en) 2024-10-10
KR20230066402A (ko) 2023-05-15
AU2021342333A1 (en) 2023-04-06
US20240226284A1 (en) 2024-07-11
MX2023002843A (es) 2023-03-31
WO2022053608A1 (en) 2022-03-17
CA3194812A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
BR112022001947A2 (pt) Combinações e composições de rna com propriedades imunoestimuladoras reduzidas
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
NZ746901A (en) Bicyclic compounds for diagnosis and therapy
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112012008962A2 (pt) derivados espiro-condensados de ciclohexano como inibidores de hsl úteis para o tratamento de diabetes
BR112022009216A2 (pt) Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
BR112022021823A2 (pt) Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria
BR112022007721A2 (pt) Método para o tratamento da demência
BR112023003432A2 (pt) Regime de tratamento para o tratamento de doenças autoimunes
BR112019009495A2 (pt) métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
BR112017010599A2 (pt) análogos de ureia ligada substituída como moduladores sirtuin
BR112019005995A2 (pt) cristal não solvatado, método de preparação e aplicação do mesmo
BR112021017436A2 (pt) Composições farmacêuticas para tratamento de doenças ou transtornos oculares
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
AR066732A1 (es) Lentes disenadas para el tratamiento de la astenopia causada por defectos visuales
BR112022020020A2 (pt) Métodos de tratamento da doença do coronavírus 2019
CO2021016487A2 (es) Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
Esmail The diagnosis and management of Parkinson’s disease
CO2024007361A2 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
AR092842A1 (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
UY36099A (es) Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
BR112023019795A2 (pt) Composições nasais compreendendo alcaftadina
BR112021023251A2 (pt) Tratamento da doença ocular
BR112022012365A2 (pt) Tratamento de lesão cerebral traumática leve